GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

ADC Therapeutics ADCT · USD

Health Care · US listing · 🇺🇸 United States

Compare

1.67

+5.70%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Company facts

Sector
Health Care
Industry
Biotechnology
Employees
188
Head office
BIOPOLE, EPALINGES, V8, 1066
Incorporated in
V8
Classification
Pharmaceutical Preparations
Filer status
Non-accelerated filer<br>Smaller reporting company

Leadership

Pay as last reported

  • Mr. Ron SquarerNon-Executive Chairman of the Board$225,473
  • Mr. Ameet MallikChief Executive Officer, Director, since 2022$1.8m
  • Mr. Jose CarmonaChief Financial Officer$933,585
  • Mr. Peter GrahamChief Legal and Compliance Officer and Secretary
  • Mr. Mohamed ZakiChief Medical Officer$1.0m
  • Mr. Robert AzelbyNon-Executive Independent Director$193,900
  • Mr. Jean Pierre BizzariNon-Executive Independent Director$189,727
  • Dr. Peter HugNon-Executive Independent Director$227,435
  • Ms. Viviane MongesNon-Executive Independent Director$233,058
  • Dr. Tyrell RiversNon-Executive Independent Director
  • Dr. Victor SandorNon-Executive Independent Director$193,900
  • Ms. Nicole RileyInvestor Relations, since 2024

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
57
Environment
35
Social
92
Governance
45
Women in the workforce
52%
Carbon reduction policy
No
Human rights policy
No

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Unique and innovative technology platform for developing antibody drug conjugates (ADCs).
  • Strong intellectual property portfolio providing competitive advantage.
  • Strategic partnerships with leading pharmaceutical companies for product development.

Weaknesses

  • Relatively small-scale operations compared to established pharmaceutical companies.
  • High dependency on successful research and development outcomes.
  • Limited marketing and distribution capabilities.

Opportunities

  • Growing demand for targeted therapeutics, including ADCs, in the pharmaceutical industry.
  • Expansion into new geographic markets for increased market reach.
  • Potential for collaboration with academic institutions to enhance R&D capabilities.

Threats

  • Intense competition from established pharmaceutical companies and emerging biotech firms.
  • Regulatory and approval challenges related to drug development and commercialization.
  • Potential for changes in government policies affecting healthcare industry.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.